Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure

J Pharmacol Exp Ther. 2001 Jul;298(1):188-96.

Abstract

The beta2-adrenergic receptor (beta2-AR)-mediated increase in cardiac L-type Ca2+ current (I(Ca,L)) has been documented in normal subjects. However, the role and mechanism of beta2-AR activation on I(Ca,L) in heart failure (HF) are unclear. Accordingly, we compared the effect of zinterol (ZIN), a highly selective beta2-AR agonist, on I(Ca,L) in isolated left ventricular cardiomyocytes obtained from normal control and age-matched rats with HF induced by left coronary artery ligation (4 months). I(Ca,L) was measured by using the whole-cell voltage-clamp technique. In normal myocytes, superfusion of ZIN (10(-5) M) caused a 21% increase in I(Ca,L) (9.21 +/- 0.24 versus 7.59 +/- 0.20 pA/pF) (p < 0.05). In HF myocytes, the same concentration of ZIN produced a significantly greater increase (30%) in I(Ca,L) (6.20 +/- 0.24 versus 4.75 +/- 0.17 pA/pF) (p < 0.01). This ZIN-induced increase in I(Ca,L) was further augmented in both normal and HF myocytes (normal: 59 versus 21%; HF: 71 versus 30%) after the incubation of myocytes with pertussis toxin (PTX, 2 microg/ml, 36 degrees C, 6 h). These effects were not modified by the incubation of myocytes with CGP-20712A (3 x 10(-7) M), a beta1-AR antagonist, but were abolished by pretreatment of myocytes with ICI-118551 (10(-7) M), a beta2-AR antagonist. In addition, all of the effects induced by ZIN were completely prevented in the presence of an inhibitory cAMP analog, Rp-cAMPS (100 microM, in the patch-pipette solution). In conclusion, beta2-AR activation stimulates L-type Ca2+ channels and increases I(Ca,L) in both normal and HF myocytes. In HF, beta2-AR activation-induced augmentation of I(Ca,L) was increased. These effects are likely to be mediated through a cAMP-dependent mechanism and coupled with both stimulatory G protein and PTX-sensitive G protein.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology*
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Calcium Channels, L-Type / drug effects*
  • Calcium Channels, L-Type / physiology
  • Cyclic AMP / metabolism
  • Ethanolamines / pharmacology*
  • GTP-Binding Protein alpha Subunits, Gi-Go / drug effects
  • GTP-Binding Protein alpha Subunits, Gi-Go / physiology
  • GTP-Binding Protein alpha Subunits, Gs / drug effects
  • GTP-Binding Protein alpha Subunits, Gs / physiology
  • Heart / drug effects*
  • Heart / physiology
  • Heart Failure / physiopathology*
  • Male
  • Myocardium / cytology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, beta-2 / drug effects*
  • Receptors, Adrenergic, beta-2 / physiology
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Left / physiology

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Calcium Channels, L-Type
  • Ethanolamines
  • Receptors, Adrenergic, beta-2
  • zinterol
  • Cyclic AMP
  • GTP-Binding Protein alpha Subunits, Gi-Go
  • GTP-Binding Protein alpha Subunits, Gs